NCT02894008View on ClinicalTrials.gov

A Study of a New Leishmania Vaccine Candidate ChAd63-KH

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

September 30, 2019

Study Completion Date

December 31, 2019

Conditions
Leishmaniasis, Cutaneous
Interventions
DRUG

ChAd63-KH

ChAd63-KH in adults and adolescents with persistent PKDL.

Trial Locations (1)

Unknown

Centre for Tropical Medicine, Doka

All Listed Sponsors
collaborator

University of Khartoum

OTHER

lead

University of York

OTHER

NCT02894008 - A Study of a New Leishmania Vaccine Candidate ChAd63-KH | Biotech Hunter | Biotech Hunter